Testicular Cancer Treatment Regimens
Get the latest treatment regimens for testicular cancer, including options such as carboplatin, EP + cisplatin, BEP, and VIP.
Testicular Cancer
Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
Recent research shows that although testicular cancer survivors do not totally conform to the criteria for metabolic syndrome, past treatment with platinum-based chemotherapy increases its prevalence among survivors and may lead to a greater risk for heart disease in this patient population.
Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
Results from the ongoing Platinum Study revealed the prevalence of risk factors for CVD among survivors of testicular cancer who received chemotherapy for their cancer.
Metabolic Syndrome More Likely After Platinum-Based Chemotherapy for Testicular Cancer
Survivors of testicular cancer are more likely to develop metabolic syndrome after platinum-based chemotherapy.
Insurance Status Linked to Survival in Patients With Testicular Cancer
Patients without insurance and those with Medicaid have an increased risk of presenting with advanced testicular cancer and cancer-related death compared with those who have insurance.
Radiation Therapy Better Than Chemotherapy for Stage IIA Testicular Cancer
Patients with stage IIA testicular cancer gain a survival advantage from treatment with radiation therapy compared with chemotherapy.
Genetic Variants Indicate 10-fold Increased Risk of Testicular Cancer
A new study has uncovered four new genetic variants associated with increased risk of testicular cancer. Testing for these and all 21 previously identified variants using genetic sequencing identified men at higher risk of testicular cancer.
New Test Predicts Relapse of Testicular Cancer
Scientists have developed a test that assesses 3 features of nonseminomatous germ cell tumor, a common kind of testicular cancer, to identify those patients at greatest risk of relapse.
Testicular cancer survivors may have increased fatigue
Recent study explored whether chronic fatigue is more prevalent in survivors of testicular cancer than the general population.
Chemo testicular nonseminoma may increase risk of short-term CVD death
Patients with testicular nonseminoma have significantly increased cardiovascular disease mortality after chemotherapy.
